Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test

Key Takeaways Quanterix submitted an FDA 510(k) for a multi-analyte, algorithmic blood test for Alzheimer's evaluation.QTRX's test uses Simoa tech to combine five biomarkers into one readout for a broader view of disease biology.The 510(k) is backed by clinical data from over 1,800 patients across three independent cohorts.Quanterix (QTRX) recently announced the submission of a 510(k) premarket notification to the FDA for its multi-analyte algorithmic blood test designed to aid in the evaluation of patients ...